Cost implications of guideline differences in hypertension

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.444, 2004-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Guideline switch from ondansetron to granisetron cost saving

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 302, 2001-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Guideline switch from ondansetron to granisetron cost saving

Inpharma, Vol. 1, Iss. 1277, 2001-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Should Cost of Care be Considered in a Clinical Practice Guideline?

By Evans William K. Brouwers Melissa C. Bell Chaim M.

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 3, 2008-03 ,pp. : 224-226

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Genetics of Hypertension: Therapeutic Implications

By OByrne S. Caulfield M.

Drugs, Vol. 56, Iss. 2, 1998-08 ,pp. : 203-214

Adis International

Access to resources Recommend Favorite

Losartan cost effective in hypertension with LVH

Inpharma, Vol. 1, Iss. 1539, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite